Carol-Ann Galban, MD
Family Medicine · Ridgefield, CTNPI 1659309714
Payments from drug & device makers
Across 284 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$539
- Pfizer$518
- GSK$421
- Amneal Pharmaceuticals LLC$304
- Merck$231
- plus $2K from 34 others
What the payments were for
- Food & beverage$5,095100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 79 | $1,191 |
| AstraZeneca | 33 | $539 |
| Pfizer | 30 | $518 |
| GSK | 20 | $421 |
| Amneal Pharmaceuticals LLC | 15 | $304 |
| Merck | 13 | $231 |
| Johnson & Johnson | 14 | $227 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $174 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $173 |
| Astellas Pharma US Inc | 7 | $128 |
| Novo Nordisk | 6 | $111 |
| Eisai Inc. | 4 | $106 |
| Sumitomo Pharma America, Inc. | 4 | $104 |
| Boehringer Ingelheim | 4 | $87 |
| Exact Sciences | 3 | $66 |
| Genentech USA, Inc. | 3 | $55 |
| Bayer | 2 | $55 |
| Amarin Pharma, Inc. | 3 | $52 |
| Sunovion Pharmaceuticals Inc. | 2 | $43 |
| Seqirus USA Inc | 2 | $42 |
| Therapeuticsmd, Inc. | 2 | $41 |
| Medtronic | 2 | $41 |
| Insulet Corporation | 1 | $29 |
| Mayne Pharma Commercial LLC | 1 | $29 |
| Corium, LLC | 1 | $26 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Krystal Biotech Inc | 1 | $25 |
| Shield Therapeutics Inc | 1 | $25 |
| Lupin Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $23 |
| Organon | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Adlon Therapeutics L.p. | 1 | $20 |
| Bausch Health US, LLC | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
| Cranial Technologies, Inc | 1 | $16 |
| Intra-sana Laboratories | 1 | $16 |
| Novartis | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
How this compares
$5,095 in reported general payments places this provider in the 85th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $52,098 |
| EliquisApixaban | 25 | $28,102 |
| JanuviaSitagliptin Phosphate | 33 | $23,572 |
| XareltoRivaroxaban | 16 | $18,442 |
| MounjaroTirzepatide | 12 | $16,068 |
| MyrbetriqMirabegron | 27 | $14,348 |
| SynthroidLevothyroxine Sodium | 83 | $8,826 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $6,762 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,083 |
| Tegretol XrCarbamazepine | 12 | $4,509 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,409 |
| Levothyroxine Sodium | 294 | $4,005 |
| Estradiol | 34 | $3,076 |
| Atorvastatin Calcium | 260 | $2,882 |
| Rosuvastatin Calcium | 125 | $1,667 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $111 | $52,09842 claims |
| MerckJanuvia, Janumet | $231 | $30,33445 claims |
| PfizerEliquis | $518 | $28,10225 claims |
| Johnson & JohnsonXarelto | $227 | $18,44216 claims |
| Astellas Pharma US IncMyrbetriq | $128 | $14,34827 claims |
| AbbVieSynthroid | $1,191 | $8,82683 claims |
| AstraZenecaBreztri Aerosphere | $539 | $6,08311 claims |
| GSKBreo Ellipta | $421 | $4,40911 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $304 | $4,005294 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Ridgefield
- James AhernRidgefield$7K
- Debra GramlichStamford$292K
- Hadrian HolderNew Haven$213K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
- Andrew SelingerBristol$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.